ClinVar Miner

Submissions for variant NM_000059.4(BRCA2):c.6275T>C (p.Leu2092Pro)

dbSNP: rs2072550918
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Labcorp Genetics (formerly Invitae), Labcorp RCV001057688 SCV001222192 uncertain significance Hereditary breast ovarian cancer syndrome 2019-05-06 criteria provided, single submitter clinical testing In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The proline amino acid residue is found in multiple mammalian species, suggesting that this missense change does not adversely affect protein function. These predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has not been reported in the literature in individuals with BRCA2-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change replaces leucine with proline at codon 2092 of the BRCA2 protein (p.Leu2092Pro). The leucine residue is weakly conserved and there is a moderate physicochemical difference between leucine and proline.
Ambry Genetics RCV002355051 SCV002655892 uncertain significance Hereditary cancer-predisposing syndrome 2022-04-05 criteria provided, single submitter clinical testing The p.L2092P variant (also known as c.6275T>C), located in coding exon 10 of the BRCA2 gene, results from a T to C substitution at nucleotide position 6275. The leucine at codon 2092 is replaced by proline, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
University of Washington Department of Laboratory Medicine, University of Washington RCV002355051 SCV003852382 likely benign Hereditary cancer-predisposing syndrome 2023-03-23 criteria provided, single submitter curation Missense variant in a coldspot region where missense variants are very unlikely to be pathogenic (PMID:31911673).

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.